

EU (MA) number	Invented name	Strength	Pharmaceutical form	Target species	Route of administration	Immediate packaging	Content	Package size	Withdrawal period
EU/2/20/262/001	Enteroporc Coli AC	--1	Lyophilisate and suspension for suspension for injection	Pigs	Intramuscular use	Lyophilisate: vial (glass); suspension: vial (glass)	Lyophilisate: 10 doses (10 ml); suspension: 20 ml	Lyophilisate: 1 vial; suspension: 1 vial	Zero days
EU/2/20/262/002	Enteroporc Coli AC	--1	Lyophilisate and suspension for suspension for injection	Pigs	Intramuscular use	Lyophilisate: vial (glass); suspension: vial (PET)	Lyophilisate: 10 doses (10 ml); suspension: 20 ml	Lyophilisate: 1 vial; suspension: 1 vial	Zero days
EU/2/20/262/003	Enteroporc Coli AC	--1	Lyophilisate and suspension for suspension for injection	Pigs	Intramuscular use	Lyophilisate: vial (glass); suspension: vial (glass)	Lyophilisate: 25 doses (10 ml); suspension: 50 ml	Lyophilisate: 1 vial; suspension: 1 vial	Zero days
EU/2/20/262/004	Enteroporc Coli AC	--1	Lyophilisate and suspension for suspension for injection	Pigs	Intramuscular use	Lyophilisate: vial (glass); suspension: vial (PET)	Lyophilisate: 25 doses (10 ml); suspension: 50 ml	Lyophilisate: 1 vial; suspension: 1 vial	Zero days

--1 *C. perfringens* components:

- Type A, alpha toxoid ≥ 125 rU/ml*
- Type C, beta1 toxoid ≥ 3354 rU/ml*
- Type A, beta2 toxoid ≥ 794 rU/ml*

E. coli components:

- F4ab fimbrial adhesin ≥ 23 rU/ml*
- F4ac fimbrial adhesin ≥ 19 rU/ml*
- F5 fimbrial adhesin ≥ 13 rU/ml*
- F6 fimbrial adhesin ≥ 37 rU/ml*

* toxoid and fimbrial adhesins content in relative units per ml, determined by ELISA against an internal standard.